What is Maravai Lifesciences Holdings, Inc.'s earnings per share (EPS)?

Maravai Lifesciences Holdings, Inc. (MRVI) reported diluted earnings per share of -$0.90 for fiscal year 2025. This represents a 14.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Maravai Lifesciences Holdings, Inc. Financials

MRVI

Trailing 12 months to June 30, 2026

Revenue $208.8M -5.0% YoY

Net Income -$77.4M +59.8% YoY

EPS (Diluted) -$0.52 +61.2% YoY

Free Cash Flow -$35.8M +16.6% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 7, 2026 Currency USD FYE December

Maravai Lifesciences Holdings, Inc. (MRVI) reported $208.8M in revenue over the twelve months to Jun 30, 2026, down 5.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MRVI FY2025 2026-05-08

Shrinking sales and a gross-margin collapse have left the company’s operating structure too large for current demand.

The hardest-to-see change is that gross margin fell from 80.9% in FY2022 to 18.3% in FY2025, so the business is not just smaller; each dollar of sales is contributing far less to cover fixed overhead. With only $34M of gross profit in FY2025 against roughly $163M of SG&A plus R&D, the company is now carrying a cost base built for a very different revenue level.

The balance sheet still looks liquid at first glance because the current ratio was 6.6x in FY2025, but cash versus debt flipped from net cash of $56.3M in FY2023 to net debt of -$69.4M. That means near-term obligations appear manageable, yet the balance sheet is no longer providing the same cushion against continued operating pressure.

Cash conversion has also weakened materially: free cash flow stayed positive at $60.7M in FY2023 despite a net loss, but reached -$70.7M by FY2025. When reported losses and cash burn deteriorate together, it usually means the downturn has moved beyond accounting charges and into the day-to-day economics of the business.

Financial Health Signals

Financial Health Score 25/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Maravai Lifesciences Holdings, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

Not available for Maravai Lifesciences Holdings, Inc., and counted as zero in the overall score.

R&D Intensity

Revenue Progress

Burn Trend

Not available for Maravai Lifesciences Holdings, Inc., and counted as zero in the overall score.

Balance Sheet

Altman Z-Score Safe

3.06

Maravai Lifesciences Holdings, Inc. scores 3.06, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($3.1B) relative to total liabilities ($558.2M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/8

Maravai Lifesciences Holdings, Inc. passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Maravai Lifesciences Holdings, Inc. reported a net loss of $130.8M while operations used $57.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Maravai Lifesciences Holdings, Inc. reported an operating loss of $215.3M against $27.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$185.7M

YoY-28.3%

5Y CAGR-8.1%

Maravai Lifesciences Holdings, Inc. generated $185.7M in revenue in fiscal year 2025. This represents a decrease of 28.3% from the prior year.

EBITDA

-$163.8M

YoY+12.5%

Maravai Lifesciences Holdings, Inc.'s EBITDA was -$163.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 12.5% from the prior year.

Net Income

-$130.8M

YoY+9.7%

Maravai Lifesciences Holdings, Inc. reported -$130.8M in net income in fiscal year 2025. This represents an increase of 9.7% from the prior year.

EPS (Diluted)

-$0.90

YoY+14.3%

Maravai Lifesciences Holdings, Inc. earned -$0.90 per diluted share (EPS) in fiscal year 2025. This represents an increase of 14.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$70.7M

YoY-218.7%

Maravai Lifesciences Holdings, Inc. recorded an outflow of $70.7M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 218.7% from the prior year.

Cash & Debt

$216.9M

YoY-32.7%

5Y CAGR-1.7%

Maravai Lifesciences Holdings, Inc. held $216.9M in cash against $286.3M in long-term debt as of fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Shares Outstanding

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin

18.3%

YoY-23.5pp

5Y CAGR-53.7pp

Maravai Lifesciences Holdings, Inc.'s gross margin was 18.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 23.5 percentage points from the prior year.

Net Margin

-70.4%

YoY-14.6pp

5Y CAGR-101.7pp

Maravai Lifesciences Holdings, Inc.'s net profit margin was -70.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 14.6 percentage points from the prior year.

Return on Equity

-61.6%

YoY-17.1pp

5Y CAGR-162.1pp

Maravai Lifesciences Holdings, Inc.'s ROE was -61.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 17.1 percentage points from the prior year.

Operating Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$17.4M

YoY-9.5%

5Y CAGR+13.3%

Maravai Lifesciences Holdings, Inc. invested $17.4M in research and development in fiscal year 2025. This represents a decrease of 9.5% from the prior year.

Capital Expenditures

$13.1M

YoY-55.7%

5Y CAGR-12.3%

Maravai Lifesciences Holdings, Inc. invested $13.1M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 55.7% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

MRVI Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

MRVI quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$208.8M	$185.7M-28.3%	$259.2M-10.3%	$288.9M-67.3%	$883.0M+10.5%	$799.2M+181.3%	$284.1M+98.5%	$143.1M
Cost of Revenue	$135.9M	$151.8M+0.6%	$150.9M+1.4%	$148.7M-12.0%	$169.0M+20.2%	$140.6M+76.5%	$79.6M+19.1%	$66.8M
Gross Profit	$72.8M	$34.0M-68.6%	$108.3M-22.7%	$140.2M-80.4%	$714.0M+8.4%	$658.7M+222.2%	$204.4M+168.0%	$76.3M
R&D Expenses	$15.2M	$17.4M-9.5%	$19.2M+11.2%	$17.3M-5.9%	$18.4M+20.7%	$15.2M+63.6%	$9.3M+156.5%	$3.6M
SG&A Expenses	$128.0M	$145.1M-10.3%	$161.8M+6.9%	$151.4M+17.1%	$129.3M+29.2%	$100.1M+6.2%	$94.2M+94.9%	$48.4M
Operating Income	-$117.1M	-$215.3M+8.6%	-$235.6M-644.5%	-$31.6M-105.5%	$574.2M+3.5%	$554.6M+362.6%	$119.9M+399.8%	$24.0M
Interest Expense	$24.0M	$27.0M-43.4%	$47.7M+3.9%	$45.9M+124.8%	$20.4M-32.5%	$30.3M-1.6%	$30.7M+2.6%	$30.0M
Income Tax	-$408K	-$4.2M-126.5%	-$1.9M-100.2%	$756.1M+1143.4%	$60.8M-1.1%	$61.5M+2035.9%	$2.9M+541.7%	-$652K
Net Income	-$77.4M	-$130.8M+9.7%	-$144.8M-4.6%	-$138.4M-128.2%	$490.7M+4.6%	$469.3M+427.5%	$89.0M+2090.4%	-$4.5M
EPS (Diluted)	-$0.52	-$0.90+14.3%	-$1.05-16.7%	-$0.90	$1.67+7.1%	$1.56	$2.36	-$0.03

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$51.4M-21.9%	$65.8M+32.0%	$49.9M+19.8%	$41.6M-12.2%	$47.4M+1.2%	$46.9M-17.2%	$56.6M-18.1%	$69.0M
Cost of Revenue	$30.8M-4.2%	$32.1M-13.2%	$37.0M+2.9%	$36.0M-9.2%	$39.6M+1.3%	$39.1M+5.3%	$37.2M+1.0%	$36.8M
Gross Profit	$20.6M-38.7%	$33.7M+162.4%	$12.8M+127.1%	$5.7M-27.2%	$7.8M+0.6%	$7.7M-60.2%	$19.4M-39.8%	$32.2M
R&D Expenses	$3.7M-4.8%	$3.9M+2.7%	$3.8M-1.5%	$3.8M-21.3%	$4.9M-0.1%	$4.9M+7.2%	$4.6M-3.0%	$4.7M
SG&A Expenses	$32.1M+10.2%	$29.1M-7.5%	$31.4M-11.2%	$35.4M-8.6%	$38.7M-2.1%	$39.6M-4.1%	$41.2M+5.5%	$39.1M
Operating Income	-$15.1M-599.2%	-$2.2M+96.3%	-$58.8M-43.3%	-$41.0M+38.1%	-$66.3M-34.8%	-$49.2M-30.4%	-$37.7M+77.2%	-$165.6M
Interest Expense	$4.8M-16.4%	$5.7M-12.3%	$6.6M-4.2%	$6.8M+0.4%	$6.8M+0.5%	$6.8M-39.8%	$11.3M-17.4%	$13.6M
Income Tax	-$171K-13.2%	-$151K-2616.7%	$6K+106.5%	-$92K+97.9%	-$4.3M-2746.9%	$162K+2414.3%	-$7K-102.3%	$311K
Net Income	-$12.4M-232.6%	-$3.7M+89.5%	-$35.7M-39.7%	-$25.6M+35.4%	-$39.6M-32.2%	-$29.9M-15.8%	-$25.9M+73.4%	-$97.1M
EPS (Diluted)	-$0.08-300.0%	-$0.02+91.7%	-$0.24-33.3%	-$0.18+33.3%	-$0.27-28.6%	-$0.21-16.7%	-$0.18+73.5%	-$0.68

MRVI Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

MRVI quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$770.6M-23.6%	$1.0B-32.2%	$1.5B-34.8%	$2.3B+19.0%	$1.9B+51.0%	$1.3B	N/A
Current Assets	$296.3M-31.0%	$429.1M-38.7%	$699.9M-17.5%	$847.9M+14.6%	$740.0M+123.2%	$331.6M	N/A
Cash & Equivalents	$216.9M-32.7%	$322.4M-43.9%	$575.0M-9.0%	$632.1M+14.7%	$551.3M+133.4%	$236.2M+856.2%	$24.7M
Inventory	$40.5M-19.1%	$50.1M-2.6%	$51.4M+19.1%	$43.2M-16.3%	$51.6M+54.8%	$33.3M	N/A
Accounts Receivable	$25.5M-33.8%	$38.5M-29.5%	$54.6M-60.6%	$138.6M+18.0%	$117.5M+130.3%	$51.0M	N/A
Goodwill	$129.4M-19.0%	$159.9M-51.0%	$326.0M+14.9%	$283.7M+85.7%	$152.8M-31.9%	$224.3M	N/A
Total Liabilities	$558.2M-18.3%	$683.0M-36.2%	$1.1B-22.2%	$1.4B+0.3%	$1.4B+23.0%	$1.1B	N/A
Current Liabilities	$44.9M-21.2%	$57.0M-34.9%	$87.5M-20.6%	$110.1M+17.5%	$93.8M-28.3%	$130.8M	N/A
Long-Term Debt	$286.3M-1.4%	$290.5M-44.0%	$518.7M-0.6%	$522.0M-0.5%	$524.6M-0.8%	$528.6M	N/A
Total Equity	$212.4M-34.7%	$325.3M-21.9%	$416.8M-23.6%	$545.2M+72.8%	$315.5M+256.5%	$88.5M-38.8%	$144.6M
Retained Earnings	$10.1M-92.8%	$140.9M-50.7%	$285.7M-29.4%	$404.8M+119.3%	$184.6M+21511.4%	$854K	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$603.7M-15.3%	$713.2M-7.4%	$770.6M-9.3%	$849.2M-5.3%	$897.0M-6.5%	$959.8M-4.8%	$1.0B-21.1%	$1.3B
Current Assets	$155.7M-38.2%	$251.7M-15.0%	$296.3M-9.1%	$325.9M-9.4%	$359.8M-4.4%	$376.3M-12.3%	$429.1M-36.8%	$679.1M
Cash & Equivalents	$70.1M-57.8%	$165.9M-23.5%	$216.9M-11.0%	$243.6M-9.8%	$269.9M-5.3%	$285.1M-11.6%	$322.4M-44.2%	$578.2M
Inventory	$41.2M+1.9%	$40.5M-0.1%	$40.5M-10.7%	$45.3M-2.9%	$46.7M-6.2%	$49.8M-0.6%	$50.1M-0.9%	$50.5M
Accounts Receivable	$31.1M-6.8%	$33.4M+31.0%	$25.5M+13.1%	$22.5M-19.2%	$27.9M-2.1%	$28.5M-26.0%	$38.5M+33.8%	$28.8M
Goodwill	$129.4M0.0%	$129.4M0.0%	$129.4M0.0%	$129.4M0.0%	$129.4M-19.0%	$159.9M0.0%	$159.9M-6.9%	$171.8M
Total Liabilities	$399.1M-20.4%	$501.7M-10.1%	$558.2M-7.5%	$603.7M-4.3%	$631.1M-4.3%	$659.1M-3.5%	$683.0M-26.8%	$933.4M
Current Liabilities	$38.4M-9.9%	$42.6M-5.1%	$44.9M-27.1%	$61.6M-11.6%	$69.7M+10.3%	$63.2M+10.9%	$57.0M-10.6%	$63.7M
Long-Term Debt	$146.0M-38.0%	$235.6M-17.7%	$286.3M-0.4%	$287.4M-0.4%	$288.4M-0.4%	$289.5M-0.3%	$290.5M-43.7%	$516.3M
Total Equity	$204.6M-3.3%	$211.6M-0.4%	$212.4M-13.5%	$245.4M-7.7%	$265.9M-11.6%	$300.6M-7.6%	$325.3M-5.7%	$344.9M
Retained Earnings	-$6.0M-194.5%	$6.4M-36.9%	$10.1M-77.9%	$45.8M-35.8%	$71.4M-35.7%	$110.9M-21.3%	$140.9M-15.5%	$166.8M

MRVI Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

MRVI quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$25.3M	-$57.6M-871.2%	$7.5M-94.1%	$126.2M-76.4%	$536.0M+45.4%	$368.6M+142.2%	$152.2M+531.1%	$24.1M
Capital Expenditures	$10.6M	$13.1M-55.7%	$29.7M-54.8%	$65.6M+283.6%	$17.1M+15.1%	$14.8M-41.6%	$25.4M+48.2%	$17.1M
Free Cash Flow	-$35.8M	-$70.7M-218.7%	-$22.2M-136.6%	$60.7M-88.3%	$518.9M+46.7%	$353.7M+179.0%	$126.8M+1719.7%	$7.0M
Investing Cash Flow	-$9.8M	-$31.4M-29.2%	-$24.3M+80.1%	-$122.3M+54.3%	-$267.6M-353.3%	$105.7M+1641.2%	$6.1M+135.4%	-$17.1M
Financing Cash Flow	-$164.3M	-$16.5M+93.0%	-$235.7M-285.8%	-$61.1M+67.4%	-$187.5M-17.9%	-$159.0M-398.9%	$53.2M+1377.0%	-$4.2M
Share Buybacks	N/A	N/A	N/A	N/A	$0	$0-100.0%	$33.7M	$0

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$4.0M-53.9%	$8.7M+138.1%	-$22.8M-50.3%	-$15.2M-47.6%	-$10.3M-9.3%	-$9.4M+35.9%	-$14.6M-211.4%	$13.1M
Capital Expenditures	$370K-91.7%	$4.4M+109.9%	$2.1M-42.2%	$3.7M+27.3%	$2.9M-36.1%	$4.5M-23.0%	$5.8M-31.9%	$8.6M
Free Cash Flow	$3.6M-14.3%	$4.2M+117.0%	-$24.9M-32.3%	-$18.8M-43.2%	-$13.1M+5.4%	-$13.9M+32.2%	-$20.5M-550.8%	$4.5M
Investing Cash Flow	-$370K+91.7%	-$4.4M-109.9%	-$2.1M+27.8%	-$2.9M+9.6%	-$3.2M+86.0%	-$23.1M-369.1%	-$4.9M+45.0%	-$9.0M
Financing Cash Flow	-$99.0M-79.2%	-$55.2M-2941.1%	-$1.8M+78.0%	-$8.2M-437.7%	-$1.5M+68.7%	-$4.9M+97.9%	-$236.2M-29295.2%	$809K

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

MRVI Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

MRVI quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	18.3%-23.5pp	41.8%-6.7pp	48.5%-32.3pp	80.9%-1.5pp	82.4%+10.5pp	72.0%+18.7pp	53.3%
Operating Margin	-115.9%	-90.9%-80.0pp	-10.9%-76.0pp	65.0%-4.4pp	69.4%+27.2pp	42.2%+25.4pp	16.8%
Net Margin	-70.4%-14.6pp	-55.9%-8.0pp	-47.9%-103.5pp	55.6%-3.2pp	58.7%+27.4pp	31.3%+34.4pp	-3.1%
Return on Equity	-61.6%-17.1pp	-44.5%-11.3pp	-33.2%-123.2pp	90.0%-58.8pp	148.8%+48.2pp	100.5%+103.6pp	-3.1%
Return on Assets	-17.0%-2.6pp	-14.4%-5.1pp	-9.3%-30.8pp	21.5%-3.0pp	24.5%+17.5pp	7.0%	N/A
Current Ratio	6.60-0.9x	7.53-0.5x	8.00+0.3x	7.70-0.2x	7.89+5.4x	2.54	N/A
Debt-to-Equity	1.35+0.5x	0.89-0.4x	1.24+0.3x	0.96-0.7x	1.66-4.3x	5.97	N/A
FCF Margin	-38.1%-29.5pp	-8.6%-29.6pp	21.0%-37.8pp	58.8%+14.5pp	44.3%-0.4pp	44.6%+39.8pp	4.9%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	40.1%-11.1pp	51.2%+25.4pp	25.8%+12.2pp	13.6%-2.8pp	16.4%-0.1pp	16.5%-17.8pp	34.3%-12.4pp	46.7%
Operating Margin	-29.3%-26.1pp	-3.3%	-117.9%	-98.6%	-139.8%	-104.9%	-66.7%	-239.9%
Net Margin	-24.1%-18.5pp	-5.7%+65.9pp	-71.6%-10.2pp	-61.4%+22.1pp	-83.5%-19.6pp	-63.9%-18.2pp	-45.7%	-140.6%
Return on Equity	-6.1%-4.3pp	-1.8%+15.1pp	-16.8%-6.4pp	-10.4%+4.5pp	-14.9%-4.9pp	-10.0%-2.0pp	-7.9%+20.2pp	-28.1%
Return on Assets	-2.1%-1.5pp	-0.5%+4.1pp	-4.6%-1.6pp	-3.0%+1.4pp	-4.4%-1.3pp	-3.1%-0.6pp	-2.6%+5.0pp	-7.6%
Current Ratio	4.05-1.9x	5.91-0.7x	6.60+1.3x	5.29+0.1x	5.16-0.8x	5.96-1.6x	7.53-3.1x	10.66
Debt-to-Equity	0.71-0.4x	1.11-0.2x	1.35+0.2x	1.17+0.1x	1.08+0.1x	0.96+0.1x	0.89-0.6x	1.50
FCF Margin	7.0%+0.6pp	6.4%+56.3pp	-49.9%-4.7pp	-45.2%-17.5pp	-27.7%+1.9pp	-29.6%+6.6pp	-36.2%-42.8pp	6.6%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Mimedx Group Inc MDXG

$644.3M

Cormedix CRMD

$654.0M

180 Life Sciences Corp ATNF

$1.1B

Oric Pharmaceuticals, Inc. ORIC

$1.4B

Verve Therapeutics, Inc. VERV

$994.0M

Where Maravai Lifesciences Holdings, Inc. Ranks

Frequently Asked Questions

What is Maravai Lifesciences Holdings, Inc.'s annual revenue?

Maravai Lifesciences Holdings, Inc. (MRVI) reported $185.7M in total revenue for fiscal year 2025. This represents a -28.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Maravai Lifesciences Holdings, Inc.'s revenue growing?

Maravai Lifesciences Holdings, Inc. (MRVI) revenue declined by 28.3% year-over-year, from $259.2M to $185.7M in fiscal year 2025.

Is Maravai Lifesciences Holdings, Inc. profitable?

No, Maravai Lifesciences Holdings, Inc. (MRVI) reported a net income of -$130.8M in fiscal year 2025, with a net profit margin of -70.4%.

What is Maravai Lifesciences Holdings, Inc.'s EBITDA?

Maravai Lifesciences Holdings, Inc. (MRVI) had EBITDA of -$163.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Maravai Lifesciences Holdings, Inc. have?

As of fiscal year 2025, Maravai Lifesciences Holdings, Inc. (MRVI) had $216.9M in cash and equivalents against $286.3M in long-term debt.

What is Maravai Lifesciences Holdings, Inc.'s gross margin?

Maravai Lifesciences Holdings, Inc. (MRVI) had a gross margin of 18.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Maravai Lifesciences Holdings, Inc.'s net profit margin?

Maravai Lifesciences Holdings, Inc. (MRVI) had a net profit margin of -70.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Maravai Lifesciences Holdings, Inc.'s return on equity (ROE)?

Maravai Lifesciences Holdings, Inc. (MRVI) has a return on equity of -61.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Maravai Lifesciences Holdings, Inc.'s free cash flow?

Maravai Lifesciences Holdings, Inc. (MRVI) recorded an outflow of $70.7M in free cash flow during fiscal year 2025. This represents a -218.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Maravai Lifesciences Holdings, Inc.'s operating cash flow?

Maravai Lifesciences Holdings, Inc. (MRVI) recorded an outflow of $57.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Maravai Lifesciences Holdings, Inc.'s total assets?

Maravai Lifesciences Holdings, Inc. (MRVI) had $770.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Maravai Lifesciences Holdings, Inc.'s capital expenditures?

Maravai Lifesciences Holdings, Inc. (MRVI) invested $13.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Maravai Lifesciences Holdings, Inc. spend on research and development?

Maravai Lifesciences Holdings, Inc. (MRVI) invested $17.4M in research and development during fiscal year 2025.

What is Maravai Lifesciences Holdings, Inc.'s current ratio?

Maravai Lifesciences Holdings, Inc. (MRVI) had a current ratio of 6.60 as of fiscal year 2025, which is generally considered healthy.

What is Maravai Lifesciences Holdings, Inc.'s debt-to-equity ratio?

Maravai Lifesciences Holdings, Inc. (MRVI) had a debt-to-equity ratio of 1.35 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Maravai Lifesciences Holdings, Inc.'s return on assets (ROA)?

Maravai Lifesciences Holdings, Inc. (MRVI) had a return on assets of -17.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Maravai Lifesciences Holdings, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Maravai Lifesciences Holdings, Inc. (MRVI) held $216.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $57.6M over that year. Dividing the one by the other, the reported balance equals about 45 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Maravai Lifesciences Holdings, Inc.'s Altman Z-Score?

Maravai Lifesciences Holdings, Inc. (MRVI) has an Altman Z-Score of 3.06, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Maravai Lifesciences Holdings, Inc.'s Piotroski F-Score?

Maravai Lifesciences Holdings, Inc. (MRVI) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Maravai Lifesciences Holdings, Inc.'s earnings high quality?

Maravai Lifesciences Holdings, Inc. (MRVI) reported a net loss of $130.8M while operations used $57.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Maravai Lifesciences Holdings, Inc. cover its interest payments?

Maravai Lifesciences Holdings, Inc. (MRVI) reported an operating loss of $215.3M against $27.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Maravai Lifesciences Holdings, Inc.?

Maravai Lifesciences Holdings, Inc. (MRVI) scores 25 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.